Michael D. Allen

Array ( [id] => 17292204 [patent_doc_number] => 20210388043 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => RECOMBINANT BI-FUNCTIONAL FUSION PROTEINS BINDING CD47 AND FC GAMMA RECEPTOR, PREPARATION AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/412445 [patent_app_country] => US [patent_app_date] => 2021-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8851 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17412445 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19556467 [patent_doc_number] => 20240368259 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => ANTIBODIES AGAINST LEFTY PROTEINS [patent_app_type] => utility [patent_app_number] => 18/005833 [patent_app_country] => US [patent_app_date] => 2021-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37454 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18005833 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17337439 [patent_doc_number] => 20220003770 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => Classification and Treatment of Gastric Cancer [patent_app_type] => utility [patent_app_number] => 17/371954 [patent_app_country] => US [patent_app_date] => 2021-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10650 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17371954 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18530022 [patent_doc_number] => 20230235090 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => BISPECIFIC ANTIBODY AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/002499 [patent_app_country] => US [patent_app_date] => 2021-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24484 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18002499 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18537579 [patent_doc_number] => 20230242678 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-03 [patent_title] => ANTI-NME ANTIBODY AND METHOD OF TREATING CANCER OR CANCER METASTASIS [patent_app_type] => utility [patent_app_number] => 18/002832 [patent_app_country] => US [patent_app_date] => 2021-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44797 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -44 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18002832 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18102428 [patent_doc_number] => 11542303 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-03 [patent_title] => Peptides and combination thereof for use in the immunotherapy against cancers [patent_app_type] => utility [patent_app_number] => 17/358902 [patent_app_country] => US [patent_app_date] => 2021-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 31 [patent_no_of_words] => 38696 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17358902 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17546675 [patent_doc_number] => 20220118016 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LEUKEMIAS AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 17/356174 [patent_app_country] => US [patent_app_date] => 2021-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40282 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17356174 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18582917 [patent_doc_number] => 20230265174 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-24 [patent_title] => ANTIBODY SPECIFICALLY BINDING TO LGALS3BP, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/004029 [patent_app_country] => US [patent_app_date] => 2021-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5077 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18004029 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451504 [patent_doc_number] => 20230192782 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => RNA MOLECULES FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 18/000242 [patent_app_country] => US [patent_app_date] => 2021-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10796 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18000242 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17080634 [patent_doc_number] => 20210275640 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-09 [patent_title] => METHODS FOR ENHANCING PERMEABILITY TO BLOOD-BRAIN BARRIER, AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/327565 [patent_app_country] => US [patent_app_date] => 2021-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12227 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17327565 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451589 [patent_doc_number] => 20230192867 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => ANTIBODIES TO GARP [patent_app_type] => utility [patent_app_number] => 17/998840 [patent_app_country] => US [patent_app_date] => 2021-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33682 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17998840 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18931101 [patent_doc_number] => 11883495 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-30 [patent_title] => Anti-CD47 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 17/316152 [patent_app_country] => US [patent_app_date] => 2021-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 8 [patent_no_of_words] => 19137 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 170 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17316152 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18436051 [patent_doc_number] => 20230183345 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => ANTI-TIGIT ANTIBODY AND PREPARATION METHOD AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 17/923999 [patent_app_country] => US [patent_app_date] => 2021-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19923 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17923999 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18391445 [patent_doc_number] => 20230159663 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-25 [patent_title] => BISPECIFIC ANTIBODIES FOR TREATING CD47-ASSOCIATED DISEASES [patent_app_type] => utility [patent_app_number] => 17/996837 [patent_app_country] => US [patent_app_date] => 2021-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31869 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -66 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17996837 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19418547 [patent_doc_number] => 20240294670 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-05 [patent_title] => ANTIBODIES TO CHITINASE 3-LIKE-1 AND METHODS OF USE THEREFOR [patent_app_type] => utility [patent_app_number] => 17/996854 [patent_app_country] => US [patent_app_date] => 2021-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38705 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17996854 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18376014 [patent_doc_number] => 20230151096 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-18 [patent_title] => THERAPEUTIC TREATMENT FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIAS USING A MONOCLONAL ANTIBODY AGAINST THE PRE-T CELL RECEPTOR [patent_app_type] => utility [patent_app_number] => 17/919445 [patent_app_country] => US [patent_app_date] => 2021-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9528 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17919445 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17297937 [patent_doc_number] => 20210393776 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => BISPECIFIC FAB FUSION PROTEINS COMPRISING A CD3-BINDING FAB FRAGMENT WITH N-TERMINAL FUSION TO A BINDING DOMAIN AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/228653 [patent_app_country] => US [patent_app_date] => 2021-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40400 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17228653 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18420165 [patent_doc_number] => 20230174626 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/913264 [patent_app_country] => US [patent_app_date] => 2021-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13590 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17913264 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17067318 [patent_doc_number] => 20210269533 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => ANTI-C-MET ANTIBODY AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/193804 [patent_app_country] => US [patent_app_date] => 2021-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13233 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17193804 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18739610 [patent_doc_number] => 20230348568 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-02 [patent_title] => EPSTEIN-BARR VIRUS MONOCLONAL ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/800706 [patent_app_country] => US [patent_app_date] => 2021-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23434 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17800706 [rel_patent_id] =>[rel_patent_doc_number] =>)